Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...
Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional ...
Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...
Credit: Getty Images. The designation was based on data from the phase 2 REDWOOD-HCM trial. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to aficamten for the ...
“The SEQUOIA-HCM trial demonstrated that aficamten can reliably and safely eliminate LVOT obstruction in patients with obstructive HCM using a simple and stepwise dosing regimen, and was associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results